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Purpose/Objective: Intensity-modulated radiotherapy (IMRT) is being 
explored in various pelvic malignancies in an effort to mitigate 
treatment-related toxicity. Moreover, IMRT allows simultaneous 
differential dose delivery to multiple tumor targets (Simultaneous 
Integrated Boost, SIB), obviating sequential treatment of an initial 
volume with a subsequent boost. In addition to the convenience of a 
shortened treatment duration, theoretical benefits exist for tumor 
control too, due to hypofractionationed schedule.Our purpose is to 
evaluate the toxicity of pelvic IMRT with hypofractionated 
simultaneous integrated boost (SIB) to the prostate for patients with 
high-risk prostate cancer. 
Materials and Methods: A prospective Phase II study was initiated at 
the end of 2008. The study involved 41 consecutive patients treated 
definitively with pelvic SIB-IMRT, all of whom also received androgen 
suppression. The IMRT plans were designed to deliver 67.5 Gy in 25 
fractions (2.7 Gy/fraction) to the prostate while simultaneously 
delivering 56.25 Gy (2.25 Gy/fraction) to the seminal vesicles and 50 
Gy (2 Gy/fraction) to the pelvic lymph nodes. All subjects underwent 
ultrasound-guided transrectal placement of 3 gold intraprostatic 
fiducial markers. Daily on-line image guidance adjustments were 
made according to the positions of the fiducial markers.Acute and late 
genitourinary (GU) and gastrointestinal (GI) toxicities were scored 
according to the Radiation Therapy Oncology Group (RTOG) grading 
system.  
Results: Fiducial marker placement proceeded without complications. 
Acute GU toxicity manifested in 12 patients (29%) as grade 1 or 2 
urethritis. No patients developed urinary retention and episode of 
gross hematuria. Acute GI toxicity manifested in 5 patients (12%) as 
grade 1 or 2. No cases of rectal bleeding were observed. With a 
follow-up time ranging from 6 to 46 months, no late bladder and 
rectal complications have been observed so far.  
Conclusions: Pelvic IMRT with hypofractionated SIB to prostate was 
well tolerated in this study, with low rates of Grade 2 acute and late 
toxicity. SIB-IMRT combines pelvic radiotherapy and hypofractionation 
to the primary site and offers an accelerated approach to treating 
high-risk disease. Additional follow-up is necessary to fully define the 
long-term toxicity after hypofractionated, whole pelvic treatment 
combined with androgen suppression. 
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Purpose/Objective: Aim of this study was to test dosimetric 
parameters able to predict possible acute Genito-Urinary (GU) toxicity 
in prostate cancer patients treated with Simultaneous Integrated 
Boost (SIB). 
Materials and Methods: A prospective study was performed between 
January 2011 and March 2012 in our Institution enrolling prostate 
cancer patients. Radiotherapy was performed with volumetric Arc 
therapy technique by Linear Accelerator. The Clinical Target Volume, 
irradiated by SIB-IMRT Technique, included: prostate (CTV1, total 
dose of 80 Gy) and seminal vesicles (CTV2, total dose of 72 Gy) in 
forty fractions. We collected a series of CBCT scans during patients’ 
treatment time, and the first five was used for a treatment 
replanning. For the analysis of the GU toxicity, we divided patients 
into 2 groups: group A, patients without acute toxicity; group B 
patients with acute toxicity of any grade. Follow-up was carried out in 
our Department. Toxicity was graded according to the RTOG criteria. 
The correlations between acute GU toxicity and bladder dosimetric 
parameters were tested through logistic models. 
Results: 45 patients were included and had a total of 845 CBCT scans. 
Difference between mean PTV1 (prostate) vs PTV1r was statistically 
significant (p<0,0001). Difference between mean PTV2 (seminal 
vesicles) and PTV2r was not statistically significant (p<0,42). Bladder 
toxicity data were collected in 39/45 (87%) patients. Mean delivered 
doses of each of the 2 groups were compared: they were significantly 
higher in group B (group A 23.89 Gy vs group B 42.76 Gy, p=0,02). The 
area under the curve (AUC) of the mean dose/volume graph, traced 
for each grade of toxicity, was clear correlated with the grade of 
toxicity. 
For a dose of 25 Gy, the mean dose curve of G0 toxicity was more 
distant from the other curves G1-2-3: the median V25 was lower for 
group A (38,89%) against the value of group B (67,87%; p= 0,0085). A 
V25>50% might express the 80% of probability to envelope bladder 
toxicity of any grade (AUC =0,793, sensitivity of 73,33 and specificity 
of 88,89; p=0,0035). A dose-reduction method was used to simplify 
the evaluation of the toxicity, that is the Equivalent Uniform Dose 
(EUD). The EUD was significantly higher in patients with GU toxicity 
(group A 25.10 Gy vs group B 42.13, p=0.02). We built up a DVH-
reduction model based on estimated complication probability (NTCP) 
under EUD of the bladder: patients were distributed on or close to an 
S slope showing that TCD50 was 18 Gy. 
  
Conclusions: IGRT is one method that may reduce toxicity whilst 
maintaining high delivered treatment doses and personalizing 
treatment plans. Bladder mean dose and V25 correlate with acute GU 
toxicity and could better optimize planning procedures in treatment 
validation. Further studies with bigger series are still needed to 
confirm these finding. 
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Purpose/Objective: PSA doubling time (PSADT) has a recognized role 
in patients (pts) candidates to salvage radiotherapy (SRT) for a 
biochemical recurrence (BR) after radical prostatectomy (RP). Its role 
and the most widely accepted cut-off (10-12 months) discriminating 
between more likely local relapse and systemic progression were 
retrospectively addressed in pts typically undergoing SRT with PSA 
values at SRT much greater than those currently suggested. The study 
was aimed at investigating its reliability and ideal cut-off in pts 
candidates to very timely SRT. 
Materials and Methods: The study included 200 node-negative pts 
who received SRT for BR after RP between 1994 and 2010. BR was 
defined as the first of two or more consecutive and increasing PSA 
values >0.20 ng/mL after RP. PSADT was computed based on an 
increasing set of hormono-naïve PSA values starting from the first 
value ≥0.10 ng/mL up to the beginning of SRT (overall PSADT). PSADT 
was also computed at 3, 6, 9, 12, 18, 24 months from the first 
observation ≥0.10 ng/mL, or on 2, 3, 4, 5, 6 consequent 
measurements, when available. Biochemical relapse-free survival 
(bRFS) after SRT was considered as primary endpoint and was set as 
the time from the beginning of SRT to PSA failure after SRT (i.e. a 
single PSA >0.20 ng/mL after an SRT-induced nadir or an increase of 
serum PSA despite SRT). 
Results: After a median follow-up of 80.8 months, 44 pts (22%) 
experienced a PSA failure after SRT (33 within 5-years). The median 
overall PSADT was 8.18 months, based on a median of 4 PSA 
observations. Cox regression analysis selected as significant predictors 
for bRFS: Gleason score (2-6 vs 7-10), PSA at SRT, dose of RT, overall 
PSADT and time from RP to the first post-RP PSA value ≥0.10 ng/mL. 
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Notably, the time from RP to BR was not significant. The probability 
of 5-yr bRFS was significantly predicted by overall PSADT (p<0.0001, 
by logistic regression), with the optimal cut-off set at 5.79 months 
(sensitivity=0.67, specificity=0.72) by ROC analysis.The PSADTs, 
computed at different time points or with a different number of 
observations were always significantly correlated to the overall 
PSADT, (Spearman's correlation). However, only the PSADTs computed 
at ≥9 months or based on ≥4 observations emerged as significant 
predictors of 5-yr bRFS (logistic regression) with most informative cut-
offs of 4.6 and 6.58 months, respectively. Finally, the median PSADT 
increased as a function of time and number of observations, thus 
suggesting an effect of the dynamic selection of the patients 
(apparently, those with the poorer prognosis had started SRT earlier). 
Conclusions: Only PSADT calculated ≥9 months after the first value 
≥0.10 ng/mL and/or on ≥4 observations resulted to be predictive of 
the risk of treatment failure following SRT. This may limit its role in 
selecting patients to be addressed to very early SRT. Of note, our 
optimal cut-offs ranged from 4.6 to 6.58 months. 
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Purpose/Objective: To retrospectively evaluate and compare the 
incidence of acute genito-urinary (GU), upper gastrointestinal (uGI) 
and rectal (lGI) injuries of hypofractionation by volumetric modulation 
arc therapy or VMAT (Hypo-RapidArc group) and conventional 
fractionation by three dimensional conformal radiotherapy (3DCRT 
group) in patients with localized prostate cancer treated with 
prostatic bed irradiation, after radical prostatectomy.  
Materials and Methods: Between 2007 and 2012, 84 consecutive 
patients with clinically localized prostate cancer patients submitted 
to radical prostatectomy were irradiated to prostate bed: 41 with 
3DCRT and 43 with VMAT by RapidArc. The median age was 67 and 
68,5 years for 3DCRT and Hypo-RapidArc group respectively. The 
median dose to the prostatic bed was 70 Gy (70 - 76) with 2 Gy per 
fraction in 3DCRT group and 70Gy (70 – 72,4) with 2.5Gy (2.5 – 2.55) 
per fraction in the Hypo-RapidArc group. After radical prostatectomy, 
the median time to RT was 15 and 16 months respectively in 3DCRT 
and Hypo-RapidArc group. Acute GU, uGI e lGI toxicities after 
radiation treatment were evaluated using RTOG/EORTC medical 
scoring system.  
Results: Acute G2 GU toxicities were better in Hypo-RapidArc group 
compared to 3DRCT group: 12% versus 17% respectively in the two 
groups. Inversely, for Acute G2 intestinal toxicities, 3DCRT was well 
tolerated: for uGI no G2 were found in 3DCRT versus 7% in Hypo-
RapidArc group; for lGI G2 toxicities7% in 3DCRT versus 18% in Hypo-
RapidArcgroup. No G3 or greater toxicities were found in both groups. 
In both groups the PTV coverage is suitable: PTV mean dose is 
99.4±1.0% and 99.8±0.9% and V95% 96.3±3.6% and 95.7±8.9 for 3DRCT 
and RA group respectively. For 3DRTC group the Rectum received a 
mean dose of42.1±9.4 Gy (with V65Gy equal to 26.9±10.0 %) and the 
Bladder received 69.3±17.2Gy in mean (with the V65Gy equal to 
45.0±19.5%); and for RA group the dose decreased to 37.2±5.2 Gy 
(V65Gy 9.6±5.1%) and 39.2±13.4 (V65Gy25.2±14.4%) for Rectum and 
Bladder. 
Conclusions: The results of our study of 84 patients have shown that 
acute G2 GU are reduced using hypofractionation by RapidArc 
compared to conventional fractionation by 3DCRT, while acute G2 GI 
toxicities remains significantly better for the last one. Remarkable is 
the absence of G3 using hypofractionation by RapidArc as well as 
recorded previously with conventional fractionation by 3DCRT. Longer 
term data are awaited for late toxicity profiles and clinical efficacy in 
Hypo-RapidArc group of patients.  
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Purpose/Objective: To asses the effectiveness of online monitoring of 
prostate rotation as an indicator of the need for adaptive replanning 
in prostate patients treated with IMRT; to evaluate the possibility to 
predict large interfraction prostate rotations based on rectal filling on 
the planning CT. 
Materials and Methods: From a population of 640 prostate cancer 
patients treated with IMRT combined with online marker-based setup 
correction, 26 patients who exhibited frequent and large (>10 °) 
prostate rotations were selected for a repeat CT scan and adaptive 
replanning. The effectiveness of adaptive replanning of these patients 
was assessed by evaluating the relative decrease in the frequency of 
large prostate rotations. The correlation between rectal filling as 
determined on the planning CT and the frequency of large prostate 
rotations was analyzed. Also, for these 26 re-planned patients the 
second planning CT scan was imported in the initial IMRT plan and the 
target coverage was evaluated in order to assess the potential impact 
of no action on this group of patients.  
Results: For the 26 patients that were re-planned, the frequency of 
large prostate rotations significantly decreased by 80.7% on average 
(p<0.001) during the fractions treated with the adapted plan. No 
significant correlation was found between the rectum volume, cross-
section or diameter on the planning CT and the frequency of prostate 
rotations (p>0.05), however there seems to be a higher risk of large 
rotations in patients with a rectum diameter larger than 5 cm at the 
level of the prostate base (p=0.03). If these patients had not been re-
planned, due to the systematic change in prostate orientation the PTV 
coverage would have decreased to 90.2% on average, although the 
CTV would remain adequately covered for all patients. 
Conclusions: For prostate cancer patients treated with IMRT 
combined with fiducial-based online position verification, a relatively 
simple prostate rotation monitoring protocol is sufficient to select the 
patients in need of adaptive replanning. Rectal filling on the planning 
CT scan is not a significant predictor of the frequency of large 
prostate rotations, although patients with a large diameter of the 
rectum on the planning CT seem to have a higher chance of having 
large prostate rotations. 
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Purpose/Objective: As male life expectancy increases throughout the 
developed world the incidence of prostate cancer is also increasing. 
Better diagnostics and raised public awareness has also contributed to 
this. A significant survival benefit favouring hormone therapy and 
radical radiotherapy over hormone therapy alone in locally advanced 
prostate cancer has been shown in recent studies. Radical 
radiotherapy technology for prostate cancer has evolved significantly 
aiming to reduce toxicity to normal tissues. Taking 10 year survival as 
the standard for assessing the use of radical treatment, we looked at 
the outcomes of patients who received radical radiotherapy for 
prostate cancer commencing after their 80th birthday. 
Materials and Methods: Data was collected retrospectively of all 
patients treated with radical radiotherapy for prostate cancer after 
their 80th birthday at our centre. From 2001 to 2012 a total of 25 
patients were suitable for inclusion. Complete data was available for 
20 patients. Key measures were patient’s prostate cancer risk 
category, predicted 10 year survival (based on Charlson comorbidity 
index) and actual disease free survival.  
Results: The mean age of patients was 80.76 years (range: 80 to 84). 
Patients received external beam radiotherapy as per local guidelines 
at a dose of 74 Gray in 37 fractions (80% of cases). Patients treated 
earlier received treatment doses ranging from 64 Gray in 32 fractions 
to 70 Gray in 30 fractions. 84% of patients had stage T3 disease, PSA≥ 
20ng/ml or Gleason score of ≥ 8 making them high risk according to 
National Institute for Clinical Excellence (NICE) criteria. The 
remaining patients were categorised as intermediate risk. No patients 
had nodal or distant metastases on imaging. All patients had a 
predicted 10 year survival of ≤ 2.25%, based on the Charlson 
comorbidity index. It is known that 4 patients have died. In 2 cases, 
the cause of death was unrelated; one from primary lung cancer and 
one from oesophageal cancer. The median disease free survival was 24 
months (range: 4 to 104). Median follow-up was 22 months. 
Conclusions: Patients in this age group have a low 10 year survival 
even without the presence of prostate cancer. By including 
intermediate to high risk prostate cancer, as in this series, this 
becomes even less. However, this 12 year series demonstrates that 
with careful selection a reasonable disease free survival can be 
achieved in this group of elderly men. Rather than basing decisions on 
predicted 10 year survival, radical radiotherapy should be carefully 
discussed with men over 80 with potentially curable prostate cancer 
on a patient by patient basis. We intend to create a prospective 
database of such patients in the future to further investigate the 
